Gerresheimer stock at EUR 28.56, target sits 1.5 percent higher

Published on 10/09/2026 at 17:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

LBBW raised its target to EUR 29.00 on October 6, 2026. Gerresheimer stock costs EUR 28.56 on October 9, 2026 versus EUR 28.41.

Key points in brief

Gerresheimer stock was EUR 28.56 at Lang & Schwarz on October 9, 2026, up 0.53 percent versus EUR 28.41.
The price stood 10.75 percent below its EUR 32.00 52-week high.
LBBW raised its target from EUR 28.00 to EUR 29.00 and kept a Hold rating on October 6, 2026.
Gerresheimer had a market capitalization of EUR 985.8 million and a negative P/E ratio of -2.46 as of October 9, 2026.

Automatisierte Glasampullen-Produktionslinie in steriler Pharmafabrik — Gerresheimer AG mit ISIN DE000A0LD6E6 produziert Glasampullen in hochautomatisierter, steriler Pharmaverpackungsfertigung mit modernster Anlagentechnik, Illustration mit AI erstellt.

Gerresheimer (ISIN DE000A0LD6E6) was trading at EUR 28.56 at Lang & Schwarz on October 9, 2026 at 4:50 p.m. CEST, up 0.53 percent versus the prior close of EUR 28.41. The price leaves 1.54 percent to the EUR 29.00 target that Goldesel reported for LBBW on October 6, 2026, up from EUR 28.00 while the bank kept its Hold rating.

Price sits below yearly high

The intraday quote was bracketed by a bid of EUR 28.50 and an ask of EUR 28.62 at Lang & Schwarz on October 9, 2026. The spread was EUR 0.12, while the quoted price remained inside the current 52-week range of EUR 14.83 to EUR 32.00.

At EUR 28.56, Gerresheimer stood 10.75 percent below the 52-week high and EUR 13.73 above the low. The finance quote showed 42,419 shares traded against an average volume of 151,932 shares as of October 9, 2026.

Target leaves 1.54 percent upside

The valuation picture remains tied to the EUR 29.00 LBBW target rather than a large target gap. LBBW's move from EUR 28.00 to EUR 29.00 represented a 3.57 percent increase in the target, but the retained Hold rating kept the assessment neutral.

Gerresheimer had a market capitalization of EUR 985.8 million and a P/E ratio of -2.46 as of October 9, 2026. The negative ratio reflects the earnings denominator used in the quote data, so the target comparison and the price range provide the clearer numerical reference points for this report.

Comparison with peers

Gerresheimer: plus 0.53 percent, P/E -2.46, market capitalization EUR 985.8 million

SCHOTT Pharma (Frankfurt, EUR): minus 3.45 percent, P/E 26.15, market capitalization EUR 3.6 billion

Stevanato Group (Nasdaq, USD): plus 0.42 percent, P/E 35.88, market capitalization USD 5.3 billion

Next results point to November

Gerresheimer's investor calendar places the half-year report in late November 2026, while the next quarterly communication is expected in December 2026. The calendar gives the stock two dated operating checkpoints after the October 9 price snapshot, with the EUR 29.00 target providing the nearer analyst reference.

Stock quote remains the anchor

The Lang & Schwarz quote puts Gerresheimer 0.53 percent above its EUR 28.41 prior close from October 8, 2026. Against the EUR 32.00 yearly high, the EUR 28.56 price remains 10.75 percent lower.

The further course of trading is shown by the continuously updated real-time quote of Gerresheimer stock.